Your browser is no longer supported. Please, upgrade your browser.
Settings
EIGR Eiger BioPharmaceuticals, Inc. daily Stock Chart
EIGR [NASD]
Eiger BioPharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.83 Insider Own1.00% Shs Outstand24.50M Perf Week8.83%
Market Cap329.75M Forward P/E- EPS next Y-2.00 Insider Trans19.05% Shs Float24.50M Perf Month74.01%
Income-68.30M PEG- EPS next Q-0.75 Inst Own79.00% Short Float2.90% Perf Quarter16.93%
Sales- P/S- EPS this Y19.30% Inst Trans-4.81% Short Ratio1.76 Perf Half Y11.03%
Book/sh1.76 P/B7.49 EPS next Y-36.10% ROA-61.20% Target Price- Perf Year16.73%
Cash/sh3.10 P/C4.25 EPS next 5Y- ROE-105.30% 52W Range4.55 - 15.82 Perf YTD-11.48%
Dividend- P/FCF- EPS past 5Y17.00% ROI- 52W High-16.62% Beta1.43
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low189.89% ATR0.89
Employees27 Current Ratio6.10 Sales Q/Q- Oper. Margin- RSI (14)71.42 Volatility5.27% 9.68%
OptionableYes Debt/Eq0.00 EPS Q/Q30.60% Profit Margin- Rel Volume0.77 Prev Close13.16
ShortableYes LT Debt/Eq0.71 EarningsMar 19 AMC Payout- Avg Volume405.11K Price13.19
Recom1.00 SMA2030.08% SMA5062.93% SMA20023.03% Volume310,052 Change0.23%
Jun-26-19Initiated Citigroup Buy $22
Jan-29-19Initiated Robert W. Baird Outperform $47
May-09-18Initiated B. Riley FBR, Inc. Buy $24
Jan-03-18Initiated Ladenburg Thalmann Buy $32
Oct-19-17Initiated ROTH Capital Buy $35
Jun-21-17Resumed Wedbush Outperform $28 → $34
May-19-20 04:05PM  Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies PR Newswire
May-15-20 08:57AM  Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now? Zacks +5.21%
Apr-30-20 08:00AM  Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda PR Newswire -8.71%
Apr-22-20 10:05AM  Will Eiger BioPharmaceuticals Continue to Surge Higher? Zacks
Apr-09-20 06:08PM  Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays American City Business Journals +7.82%
Apr-01-20 04:05PM  Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic PR Newswire -13.24%
Mar-24-20 10:25AM  Eiger Completes NDA Submission of Progeria Drug Lonafarnib Zacks +11.88%
Mar-23-20 08:00AM  Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies PR Newswire +5.37%
Mar-20-20 06:45AM  Insider Buying: The Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Founder Just Bought US$151k Worth Of Shares Simply Wall St.
Mar-13-20 08:00AM  Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update PR Newswire +5.54%
Jan-19-20 03:04PM  Top Insider Buys Highlight for the Week of Jan. 17 GuruFocus.com
Jan-15-20 05:24AM  Trade Alert: The Chairman Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Thomas Dietz, Has Just Spent US$56k Buying Shares Simply Wall St.
Jan-07-20 08:00AM  Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer PR Newswire
Jan-06-20 08:00AM  Eiger Updates on 2019 Progress and 2020 Milestones Expected PR Newswire
Dec-16-19 05:15PM  Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies PR Newswire
Dec-07-19 01:33AM  Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR) Insider Monkey
Nov-15-19 08:00AM  Eiger to Present at Jefferies 2019 London Healthcare Conference PR Newswire
Nov-12-19 08:45AM  Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019 PR Newswire
Nov-11-19 09:58AM  Is Eiger BioPharmaceuticals, Inc. (EIGR) A Good Stock To Buy? Insider Monkey
Nov-07-19 04:05PM  Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update PR Newswire
Oct-21-19 09:00AM  Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019 PR Newswire
Oct-09-19 09:47AM  Do Institutions Own Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares? Simply Wall St.
Sep-27-19 08:00AM  Eiger to Present at Cantor 2019 Global Healthcare Conference PR Newswire
Aug-29-19 04:05PM  Eiger BioPharmaceuticals to Participate in September Conferences PR Newswire
Aug-20-19 08:00AM  Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection PR Newswire
Aug-08-19 04:05PM  Eiger BioPharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update PR Newswire
Aug-05-19 08:00AM  Eiger BioPharmaceuticals to Participate in Investor Conferences in August PR Newswire -6.37%
Jul-31-19 08:00AM  Immunotherapy startup names new CEO American City Business Journals
Jul-18-19 09:20AM  Small Peninsula biotech targets big impact on deadly childhood aging disease American City Business Journals
Jul-11-19 12:42PM  Need To Know: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Insiders Have Been Buying Shares Simply Wall St.
Jul-08-19 09:00AM  What Makes Eiger BioPharma (EIGR) a New Buy Stock Zacks +12.97%
Jun-20-19 07:08PM  Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR) Insider Monkey
Jun-18-19 07:31AM  The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
Jun-17-19 04:16PM  Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) PR Newswire
Jun-10-19 08:00AM  Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs PR Newswire
Jun-05-19 08:00AM  Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development PR Newswire
May-30-19 08:00AM  Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference PR Newswire
May-17-19 04:05PM  Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer PR Newswire
May-09-19 05:04PM  Eiger BioPharma: 1Q Earnings Snapshot Associated Press
04:01PM  Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update PR Newswire
Apr-30-19 08:00AM  Eiger to Present at ChinaBio® Partnering Forum 2019 PR Newswire
Apr-26-19 02:43PM  Do Institutions Own Shares In Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)? Simply Wall St.
Apr-23-19 03:50PM  Weekly CFO Buys Highlight GuruFocus.com
Apr-17-19 10:53PM  Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire -5.72%
04:01PM  Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
Apr-15-19 08:00AM  Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors PR Newswire
Apr-11-19 04:05PM  Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress 2019 PR Newswire
Mar-26-19 08:00AM  Eiger BioPharmaceuticals to Participate in Conferences in April PR Newswire
Mar-25-19 01:30PM  Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019 PR Newswire
Mar-20-19 08:00AM  Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 PR Newswire
Mar-15-19 09:04AM  What Makes Eiger BioPharma (EIGR) a New Buy Stock Zacks
Mar-14-19 04:19PM  Eiger BioPharma: 4Q Earnings Snapshot Associated Press
Mar-13-19 08:00AM  Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress 2019 PR Newswire
Mar-11-19 08:00AM  Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit PR Newswire
Mar-08-19 07:37PM  [$$] Five Best: Susan Froderberg on Extraordinary Mountain Ascents The Wall Street Journal
Mar-04-19 07:00AM  Clinigen and Eiger BioPharmaceuticals Launch Worldwide Managed Access Program for Lonafarnib for Patients with Progeria and Progeroid Laminopathies Business Wire
Feb-27-19 08:00AM  Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer PR Newswire
Feb-06-19 08:00AM  Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan PR Newswire
Feb-04-19 08:00AM  Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans PR Newswire
Jan-07-19 08:00AM  Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors PR Newswire +8.79%
Dec-31-18 07:30AM  Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Dec-21-18 09:25AM  Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares? Simply Wall St. -5.62%
Dec-19-18 08:00AM  Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies PR Newswire -5.34%
Dec-18-18 08:00AM  Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection PR Newswire -5.75%
Dec-17-18 08:00AM  Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection PR Newswire
Dec-11-18 02:30PM  Eiger BioPharmaceuticals Reports on 2018 R&D Day PR Newswire
Dec-04-18 08:00AM  Eiger BioPharmaceuticals to Host R&D Day in New York City PR Newswire
07:59AM  The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO Benzinga
Dec-03-18 04:05PM  Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer PR Newswire +5.56%
08:00AM  Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies PR Newswire
Nov-23-18 08:25AM  Analysis: Positioning to Benefit within Artisan Partners Asset Management, Gamco Investors, Eiger BioPharmaceuticals, Waddell & Reed Financial, AmpliPhi Biosciences, and Limbach Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +8.98%
Nov-19-18 08:00AM  Eiger to Participate in Piper Jaffray Healthcare Conference PR Newswire
Nov-09-18 08:23AM  Eiger BioPharma: 3Q Earnings Snapshot Associated Press -6.19%
08:00AM  Eiger Bio Reports Third Quarter 2018 Financial Results PR Newswire
Oct-23-18 09:00AM  Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PR Newswire
08:35AM  The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares Benzinga
Oct-22-18 04:01PM  Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire -10.01%
08:00AM  Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019 PR Newswire
Oct-18-18 08:00AM  Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference PR Newswire
07:56AM  The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs Benzinga
Oct-17-18 04:05PM  Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection PR Newswire +7.36%
08:15AM  The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise Benzinga
Oct-16-18 04:05PM  Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH) PR Newswire +7.09%
04:05PM  Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint PR Newswire
Sep-25-18 08:00AM  Eiger BioPharmaceuticals to Participate in Investor Conferences PR Newswire
Sep-24-18 08:00AM  Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018 PR Newswire
Aug-27-18 08:00AM  Eiger BioPharmaceuticals to Participate in Investor Conferences PR Newswire
Aug-13-18 08:00AM  Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia PR Newswire
Aug-10-18 08:09AM  Eiger BioPharma: 2Q Earnings Snapshot Associated Press
08:00AM  Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results PR Newswire
Aug-07-18 08:00AM  Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-06-18 08:00AM  Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health PR Newswire
Jul-31-18 08:00AM  Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection PR Newswire
Jul-19-18 07:26AM  Eiger BioPharmaceuticals (EIGR) Enters Oversold Territory Zacks
05:51AM  Eiger BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-04-18 08:00AM  Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018 PR Newswire +8.00%
May-30-18 08:00AM  Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference PR Newswire
May-24-18 09:05AM  Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PR Newswire -6.09%
08:37AM  Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings Benzinga
May-23-18 04:15PM  Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dietz Thomas JohnDirectorMar 16Buy4.951,0004,95030,000Mar 17 05:17 PM
Glenn Jeffrey SDirectorMar 16Buy5.0330,000150,81366,355Mar 17 05:16 PM
Mayer Eldon C. IIIEx VP & Chief Commerc. OfficerJan 24Buy13.525,00067,60330,000Jan 30 04:44 PM
Dietz Thomas JohnDirectorJan 10Buy13.944,00055,76024,000Jan 13 08:17 AM